Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYSLTR1 | Q9Y271 | 2/20 | 0.52 |
| ▸ | CYSLTR2 | Q9NS75 | 1/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | NCF1 | P14598 | 2/20 | 0.45 |
| ▸ | NOS2 | P35228 | 1/20 | 0.45 |
| ▸ | BACE1 | P56817 | 1/20 | 0.45 |
| ▸ | CA12 | O43570 | 1/20 | 0.45 |
| ▸ | CA9 | Q16790 | 1/20 | 0.45 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.44 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL29427168 | 1.00 | CYSLTR1 (0.52) | CYSLTR1CYSLTR2CYP1A2KMT2ANCF1 | |
| SCHEMBL29353900 | 0.98 | CYSLTR1 (0.53) | CYSLTR1CYSLTR2CYP1A2KMT2ANCF1 | |
| SCHEMBL498405 | 0.98 | CYSLTR1 (0.53) | CYSLTR1CYSLTR2CYP1A2KMT2ANCF1 | |
| Bromide SCHEMBL19281783 | 0.96 | CYSLTR1 (0.52) | CYSLTR1CYSLTR2CYP1A2KMT2ANCF1 | |
| Hydrochloric Acid SCHEMBL17395656 | 0.94 | CYSLTR1 (0.50) | CYSLTR1CYSLTR2CYP1A2KMT2ANCF1 | |
| SCHEMBL4846265 | 0.81 | PDE10A (0.50) | CYSLTR1CYSLTR2CYP1A2NCF1NOS2 | |
| SCHEMBL29693804 | 0.80 | CYSLTR1 (0.53) | CYSLTR1CYSLTR2CYP1A2NCF1NOS2 | |
| SCHEMBL9080506 | 0.80 | CYSLTR1 (0.53) | CYSLTR1CYSLTR2CYP1A2NCF1NOS2 | |
| Trifluoromethanesulfonic Acid SCHEMBL21332472 | 0.80 | CYSLTR1 (0.44) | CYSLTR1CYSLTR2CYP1A2GPBAR1 | |
| SCHEMBL2913941 | 0.79 | PDE10A (0.61) | CYSLTR1CYSLTR2CYP1A2NCF1NOS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 787 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114702441-B | Cuprous complex with anti-tumor activity and preparation method and application thereof | 山西农业大学 | 2023-04-14 | — | — | CN | claimed |
| CN-115850345-A | Quinoline functional nitrogen heterocyclic carbene ruthenium complex with multiple anti-cancer activities and preparation method thereof | 浙江树人学院 | 2023-03-28 | — | — | CN | claimed |
| CN-114702441-A | Cuprous complex with anti-tumor activity and preparation method and application thereof | 山西农业大学 | 2022-07-05 | — | — | CN | claimed |
| CN-103864824-B | Adamantyl quinoline title complex, intermediate and its preparation method and application | ANHUI NORMAL UNIVERSITY (CN) | 2016-03-30 | — | — | CN | claimed |
| CN-103604756-B | A kind of Resonance Rayleigh Scattering Technique measuring azides ion | GUANGXI NORMAL UNIVERSITY (CN) | 2016-02-03 | — | — | CN | claimed |
| CN-103864824-A | Adamantyl quinoline complex and intermediate as well as preparation method and application thereof | UNIV ANHUI NORMAL | 2014-06-18 | — | — | CN | claimed |
| CN-103604756-A | Resonance Rayleigh scattering (RRS) method for measuring azide ion | UNIV GUANGXI NORMAL | 2014-02-26 | — | — | CN | claimed |
| EP-0743574-B1 | Migration imaging members | XEROX CORP (US) | 2000-12-27 | — | — | EP | claimed |
| EP-0743573-B1 | Method for obtaining image contrast migration imaging members | XEROX CORP (US) | 2000-09-06 | — | — | EP | claimed |
| EP-0743573-A2 | Method for obtaining image contrast migration imaging members | XEROX CORPORATION (US) | 1996-11-20 | — | — | EP | claimed |
| EP-0743574-A2 | Migration imaging members | XEROX CORPORATION (US) | 1996-11-20 | — | — | EP | claimed |
| US-5563014-A | SOFTENABLE LAYER CONTAINIG PHOTOSENSITIVE MARKING MATERIAL; TRANSPARENTIZING AGENT | XEROX CORPORATION (US) | 1996-10-08 | — | — | US | claimed |
| US-5514505-A | SELECTIVE TRANSPARENTIZATION OF PHOTOSENSITIVE MIGRATION MARKING PARTICLES EMBEDDED NEAR THE SURFACE OF A SOFTENABLE LAYER SUPPORTED BY AN ELECTROCONDUCTIVE SUBSTRATE | XEROX CORPORATION (US) | 1996-05-07 | — | — | US | claimed |
| EP-0181568-A2 | Anti-inflammatory/anti-allergic compounds | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1986-05-21 | — | — | EP | claimed |
| US-4009087-A | N-HETERO AROMATIC, AND SULFOALKYL OR SULFOARYL SULFIDE | M&T CHEMICALS INC. (US) | 1977-02-22 | — | — | US | claimed |
| US-20260049102-A1 | A PRO-MOIETY FOR FORMING A PRODRUG SELECTIVELY CLEAVED BY PROSTATE-SPECIFIC ANTIGEN (PSA) | UNIV SYDNEY (AU) | 2026-02-19 | — | — | US | disclosed |
| US-20250333412-A1 | SUBSTITUTED PYRIDO[3,4-B]INDOLES FOR THE TREATMENT OF CARTILAGE DISORDERS | SANOFI SA (FR) | 2025-10-30 | — | — | US | disclosed |
| US-4110457-A | HYPOTENSIVE, CARDIOACTIVE | CIBA-GEIGY CORPORATION (US) | 1978-08-29 | — | — | US | disclosed |
| US-4091103-A | HYPOTENSIVE, CARDIOACTIVE AGENTS | CIBA-GEIGY CORPORATION (US) | 1978-05-23 | — | — | US | disclosed |
| US-4009087-A | N-HETERO AROMATIC, AND SULFOALKYL OR SULFOARYL SULFIDE | M&T CHEMICALS INC. (US) | 1977-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260049102-A1 | A PRO-MOIETY FOR FORMING A PRODRUG SELECTIVELY CLEAVED BY PROSTATE-SPECIFIC ANTIGEN (PSA) | FOLH1, PSAP, KLK3 | CYSLTR1 3709/4885CYSLTR2 3755/4885CYP1A2 3806/4885 |
| US-20250333412-A1 | SUBSTITUTED PYRIDO[3,4-B]INDOLES FOR THE TREATMENT OF CARTILAGE DISORDERS | COL2A1, IDO1, COL1A1 | CYSLTR1 457/4885CYSLTR2 868/4885CYP1A2 376/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.